JP2012506443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506443A5 JP2012506443A5 JP2011533295A JP2011533295A JP2012506443A5 JP 2012506443 A5 JP2012506443 A5 JP 2012506443A5 JP 2011533295 A JP2011533295 A JP 2011533295A JP 2011533295 A JP2011533295 A JP 2011533295A JP 2012506443 A5 JP2012506443 A5 JP 2012506443A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound according
- group
- compound
- epothilone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000001931 aliphatic group Chemical group 0.000 claims description 22
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 16
- -1 transition metal cation Chemical class 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229910052723 transition metal Inorganic materials 0.000 claims description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 8
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims description 2
- FCCNKYGSMOSYPV-DEDISHTHSA-N (-)-Epothilone E Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C FCCNKYGSMOSYPV-DEDISHTHSA-N 0.000 claims description 2
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 claims description 2
- PFJFPBDHCFMQPN-RGJAOAFDSA-N (1s,3s,7s,10r,11s,12s,16r)-3-[(e)-1-[2-(aminomethyl)-1,3-thiazol-4-yl]prop-1-en-2-yl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CN)=N1 PFJFPBDHCFMQPN-RGJAOAFDSA-N 0.000 claims description 2
- OOKIODJYZSVHDO-QMYFOHRPSA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 OOKIODJYZSVHDO-QMYFOHRPSA-N 0.000 claims description 2
- OFPZNTXZCGKCMU-VXUABRCOSA-N (3z,5e,7r,8r,10r,11z,13r,14s,15s,21r,22r)-22-[(2r,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@@H](C)[C@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@H](O)C[C@@H](O)\C=C/[C@@H](C)[C@@H](O)[C@@H](C)CC(C)CCC(O)[C@H]1C OFPZNTXZCGKCMU-VXUABRCOSA-N 0.000 claims description 2
- SCJGXQSJGQUCFA-YSMBQZINSA-N 2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline;hydrochloride Chemical compound Cl.C1=C(N)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 SCJGXQSJGQUCFA-YSMBQZINSA-N 0.000 claims description 2
- OFPZNTXZCGKCMU-QUQSCIKMSA-N Dictyostatin 1 Natural products CC(C=C/C=C)C1OC(=O)C=C/C=C/C(C)C(O)CC(O)C=C/C(C)C(O)C(C)CC(C)CCC(O)C1C OFPZNTXZCGKCMU-QUQSCIKMSA-N 0.000 claims description 2
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 2
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 claims description 2
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims description 2
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 claims description 2
- 229940119336 Microtubule stabilizer Drugs 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 claims description 2
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 2
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 claims description 2
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 2
- FCCNKYGSMOSYPV-UHFFFAOYSA-N epothilone E Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2OC2CC1C(C)=CC1=CSC(CO)=N1 FCCNKYGSMOSYPV-UHFFFAOYSA-N 0.000 claims description 2
- FCCNKYGSMOSYPV-OKOHHBBGSA-N epothilone e Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 FCCNKYGSMOSYPV-OKOHHBBGSA-N 0.000 claims description 2
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- IKIBJHWXDSKRKV-UHFFFAOYSA-N fijianolide B Natural products CC1CC(=C)CC(O)C2OC2CC(OC(=O)C=C/CC3OC(C)(CC=C3)C1)C(O)C=CC4CC(=CCO4)C IKIBJHWXDSKRKV-UHFFFAOYSA-N 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 claims description 2
- DORDKUBCRPNETF-UHFFFAOYSA-N jatropham Natural products CC1=CC(O)NC1=O DORDKUBCRPNETF-UHFFFAOYSA-N 0.000 claims description 2
- MSBQEQDLFWWWMV-XZZGLLCESA-N laulimalide Chemical compound C(/[C@H](O)[C@H]1OC(=O)\C=C/C[C@@H]2C=CC[C@H](O2)C[C@H](CC(=C)C[C@H](O)[C@@H]2O[C@H]2C1)C)=C\[C@@H]1CC(C)=CCO1 MSBQEQDLFWWWMV-XZZGLLCESA-N 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- GVNUFBXIXQNOCF-UHFFFAOYSA-N suchilactone Natural products C1=C(OC)C(OC)=CC=C1CC(COC1=O)C1=CC1=CC=C(OCO2)C2=C1 GVNUFBXIXQNOCF-UHFFFAOYSA-N 0.000 claims description 2
- 108010029464 tasidotin Proteins 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19693208P | 2008-10-22 | 2008-10-22 | |
| US61/196,932 | 2008-10-22 | ||
| PCT/US2009/061480 WO2010048284A1 (en) | 2008-10-22 | 2009-10-21 | Transition metal complexes of bis[thiohydrazide amide] compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015003335A Division JP5886986B2 (ja) | 2008-10-22 | 2015-01-09 | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012506443A JP2012506443A (ja) | 2012-03-15 |
| JP2012506443A5 true JP2012506443A5 (https=) | 2013-06-06 |
Family
ID=42119652
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533295A Pending JP2012506443A (ja) | 2008-10-22 | 2009-10-21 | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 |
| JP2015003335A Expired - Fee Related JP5886986B2 (ja) | 2008-10-22 | 2015-01-09 | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015003335A Expired - Fee Related JP5886986B2 (ja) | 2008-10-22 | 2015-01-09 | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9174935B2 (https=) |
| EP (1) | EP2349991A4 (https=) |
| JP (2) | JP2012506443A (https=) |
| KR (1) | KR20110073613A (https=) |
| CN (1) | CN102256937B (https=) |
| AU (1) | AU2009308502B2 (https=) |
| BR (1) | BRPI0919720A2 (https=) |
| CA (1) | CA2741189A1 (https=) |
| IL (1) | IL212439A (https=) |
| MX (1) | MX2011004276A (https=) |
| NZ (1) | NZ592400A (https=) |
| WO (1) | WO2010048284A1 (https=) |
| ZA (1) | ZA201103015B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI440632B (zh) | 2006-08-21 | 2014-06-11 | Synta Pharmaceuticals Corp | 用於治療增生性疾病的化合物 |
| WO2009064374A2 (en) | 2007-11-09 | 2009-05-22 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
| WO2009105257A1 (en) | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2009123704A2 (en) * | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
| MX2011004114A (es) * | 2008-10-22 | 2011-08-15 | Synta Pharmaceuticals Corp | Complejos de metales de transicion de un compuesto bis (tiohidrazida amida). |
| CN102256937B (zh) | 2008-10-22 | 2014-12-17 | 辛塔医药品有限公司 | 双[硫代酰肼酰胺]化合物的过渡金属络合物 |
| JP5631327B2 (ja) | 2008-12-01 | 2014-11-26 | シンタ ファーマシューティカルズ コーポレーション | 増殖性障害を治療するための化合物 |
| US8822532B2 (en) * | 2009-12-04 | 2014-09-02 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
| EP2560627A1 (en) | 2010-04-20 | 2013-02-27 | Synta Pharmaceuticals Corp. | Use of bis [thiohydrazide amide]compounds such as elesclomol for treating cancers |
| US20140329892A1 (en) | 2011-11-10 | 2014-11-06 | Synta Pharmaceuticals Corp. | Administration of a bis(thiohydrazide amide) compound for treating cancers |
| US20150057357A1 (en) | 2012-01-05 | 2015-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bis (thiohydrazide amide) compounds for treating cancers |
| JP6660712B2 (ja) * | 2015-11-10 | 2020-03-11 | 株式会社Ｓｃｒｅｅｎホールディングス | 分類器構成方法および細胞の生死判定方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS583499B2 (ja) | 1975-07-28 | 1983-01-21 | 旭化成株式会社 | アンテイカサレタ ポリウレタンソセイブツ |
| TWI252847B (en) | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
| TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| US6924312B2 (en) | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
| TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
| TWI330079B (en) | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
| CN1993318B (zh) | 2004-06-23 | 2012-10-03 | Synta医药公司 | 用于治疗癌症的双（硫代-酰肼酰胺）盐 |
| WO2006033913A2 (en) | 2004-09-16 | 2006-03-30 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amides) for treament of hyperplasia |
| JP5204489B2 (ja) | 2004-11-19 | 2013-06-05 | シンタ ファーマスーティカルズ コーポレイション | Ｈｓｐ７０発現を増加するためのビス（チオ‐ヒドラジドアミド） |
| US20060167106A1 (en) | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
| EP1871350A1 (en) | 2005-04-15 | 2008-01-02 | Synta Pharmaceuticals Corporation | Methods of increasing natural killer cell activity for therapy |
| WO2006113695A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
| KR20080008399A (ko) | 2005-05-16 | 2008-01-23 | 신타 파마슈티칼스 코프. | 비스(티오-히드라지드 아미드) 염의 합성 방법 |
| KR20080035642A (ko) | 2005-08-16 | 2008-04-23 | 신타 파마슈티칼스 코프. | 비스(티오-히드라지드 아미드) 제제 |
| TWI440632B (zh) | 2006-08-21 | 2014-06-11 | Synta Pharmaceuticals Corp | 用於治療增生性疾病的化合物 |
| EP2061451A2 (en) * | 2006-08-21 | 2009-05-27 | Synta Pharmaceuticals Corporation | Bis(thiohydrazide amides) for treating melanoma |
| WO2008024301A2 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma |
| TW200817348A (en) | 2006-08-21 | 2008-04-16 | Synta Pharmaceuticals Corp | Compounds for the treatment of proliferative disorders |
| US20100068174A1 (en) | 2006-08-21 | 2010-03-18 | Synta Pharmaceuticals Corp. | Combination with bis (thiohydrazide amides) for treating cancer |
| US8497272B2 (en) | 2006-08-21 | 2013-07-30 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| JP2010502616A (ja) | 2006-08-31 | 2010-01-28 | シンタ ファーマシューティカルズ コーポレーション | 癌を治療するためのビス（チオヒドラジドアミド）の組み合わせ |
| AU2007294969A1 (en) | 2006-09-11 | 2008-03-20 | Synta Pharmaceuticals Corp. | Bis (thiohydrazide amides) formulation |
| US7645904B2 (en) | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
| US20090093538A1 (en) | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
| US8093425B2 (en) | 2007-04-30 | 2012-01-10 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2009020631A2 (en) | 2007-08-07 | 2009-02-12 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| US8637704B2 (en) | 2007-11-28 | 2014-01-28 | Synta Pharmaceuticals Corp. | Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide) |
| WO2009105257A1 (en) | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
| WO2009123704A2 (en) | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
| MX2011004114A (es) | 2008-10-22 | 2011-08-15 | Synta Pharmaceuticals Corp | Complejos de metales de transicion de un compuesto bis (tiohidrazida amida). |
| CN102256937B (zh) | 2008-10-22 | 2014-12-17 | 辛塔医药品有限公司 | 双[硫代酰肼酰胺]化合物的过渡金属络合物 |
| JP5631327B2 (ja) | 2008-12-01 | 2014-11-26 | シンタ ファーマシューティカルズ コーポレーション | 増殖性障害を治療するための化合物 |
| US8822532B2 (en) * | 2009-12-04 | 2014-09-02 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
-
2009
- 2009-10-21 CN CN200980151259.3A patent/CN102256937B/zh not_active Expired - Fee Related
- 2009-10-21 MX MX2011004276A patent/MX2011004276A/es active IP Right Grant
- 2009-10-21 NZ NZ592400A patent/NZ592400A/xx not_active IP Right Cessation
- 2009-10-21 AU AU2009308502A patent/AU2009308502B2/en not_active Ceased
- 2009-10-21 US US13/125,003 patent/US9174935B2/en not_active Expired - Fee Related
- 2009-10-21 KR KR1020117011636A patent/KR20110073613A/ko not_active Ceased
- 2009-10-21 BR BRPI0919720A patent/BRPI0919720A2/pt not_active IP Right Cessation
- 2009-10-21 JP JP2011533295A patent/JP2012506443A/ja active Pending
- 2009-10-21 CA CA2741189A patent/CA2741189A1/en not_active Abandoned
- 2009-10-21 EP EP09822624.4A patent/EP2349991A4/en not_active Withdrawn
- 2009-10-21 WO PCT/US2009/061480 patent/WO2010048284A1/en not_active Ceased
-
2011
- 2011-04-17 IL IL212439A patent/IL212439A/en not_active IP Right Cessation
- 2011-04-20 ZA ZA2011/03015A patent/ZA201103015B/en unknown
-
2015
- 2015-01-09 JP JP2015003335A patent/JP5886986B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506443A5 (https=) | ||
| JP2010523670A5 (https=) | ||
| JP2011037841A5 (https=) | ||
| JP2013537240A5 (https=) | ||
| JP2011511073A5 (https=) | ||
| JP2019513770A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| JP2011511095A5 (https=) | ||
| JP2010501562A5 (https=) | ||
| JP5886986B2 (ja) | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 | |
| JP2009526830A5 (https=) | ||
| RU2012105467A (ru) | Триазолопиридиновое соединение и его действие в качестве ингибитора пролилгидроксилазы и индуктора выработки эритропоэтина | |
| JP2007509978A5 (https=) | ||
| JP2013199483A5 (https=) | ||
| JP2016006118A5 (https=) | ||
| JP2015509098A5 (https=) | ||
| JP2016526540A5 (https=) | ||
| JP2009526034A5 (https=) | ||
| JP2013507423A5 (https=) | ||
| JP2018504437A5 (https=) | ||
| JP2019507111A5 (https=) | ||
| JP2012506444A (ja) | ビス［チオヒドラジドアミド］化合物の遷移金属錯体 | |
| JP2014506907A5 (https=) | ||
| JP2018538248A5 (https=) | ||
| JP2012510475A5 (https=) |